In accordance with section 27a of Consolidated Act about Securities Trading
etc., we hereby issue a complete list of NeuroSearch announcements in 2008 and
in January - March 2009. All announcements are available under the IR section
of our homepage www.neurosearch.com.

Date / No. /
Heading

04.01.2008 01-08
NeuroSearch announces the end of stabilisation period in connection with the
rights issue, completed November 2007

17.01.2008 02-08
NeuroSearch issues 185,755 new shares to the sellers of Carlsson Research AB as
milestone payment relating to the start of ACR343 Phase I study

22.01.2008 03-08
NeuroSearch announces revised financial calendar for 2008

23.01.2008 04-08
NeuroSearch has issued 185,755 new shares in a directed issuance to the sellers
of Carlsson Research AB

31.01.2008 05-08
NeuroSearch A/S' share capital and voting rights

03.03.2008 06-08
NeuroSearch publishes positive and confirmatory results from TIPO-2, a clinical
metabolic study with tesofensine for the treatment of obesity

04.03.2008 07-08
NeuroSearch A/S - Financial statements 2007

06.03.2008 08-08
List of NeuroSearch announcements in 2007 and in January - March 2008

11.03.2008 09-08
NeuroSearch issues new shares in connection with exercise of warrants

31.03.2008 10-08
NeuroSearch initiates clinical Phase I study with NSD-788 for the treatment of
anxiety and depression

31.03.2008 11-08
NeuroSearch A/S' share capital and voting rights

15.04.2008 12-08
Changes in the board of directors of NeuroSearch A/S

15.04.2008 13-08
Notice convening ordinary general meeting in NeuroSearch

25.04.2008 14-08
NeuroSearch initiates pivotal Phase III programme with ACR16 for the treatment
of Huntington's disease

28.05.2008 15-08
Notice concerning proxies received for the Annual General Meeting of
NeuroSearch A/S

30.04.2008 16-08
NeuroSearch A/S - Q1 Report 2008

30.04.2008 17-06
Report on ordinary general meeting held in NeuroSearch A/S

05.05.2008 18-08
Notice convening Extraordinary General Meeting in NeuroSearch A/S

21.05.2008 19-08
NeuroSearch has decided to issue 300,000 new shares in a directed offering
subscribed for by institutional investors at a price of DKK 280 per share to
finance a milestone payment to the sellers of Carlsson Research AB

21.05.2008 20-08
NeuroSearch releases time schedule for the completion of the directed offering
of 300,000 new shares subscribed for by institutional investors to finance a
milestone payment to the sellers of Carlsson Research AB

21.05.2008 21-08
The shareholdings of A.J. Aamund in NeuroSearch is diluted to less than 5% in
connection with the company's issue of 300,000 new shares

23.05.2008 22-08
Report on extraordinary general meeting held in NeuroSearch A/S

26.05.2008 23-08
NeuroSearch has issued 300,000 new shares in a directed offering subscribed for
by institutional investors to finance a milestone payment related to the
initiation of a Phase III study with ACR16 in Huntington's disease

30.05.2008 24-08
NeuroSearch A/S' share capital and voting rights

20.06.2008 25-08
NeuroSearch announces positive key results from a Phase II study with ABT-894
in adults with Attention Deficit-Hyperactivity Disorder (ADHD)

26.06.2008 26-08
NeuroSearch successfully completes Phase I with ACR325 and announces the
decision to progress development into Phase II Proof-of-Concept studies in
Parkinson's disease and Bipolar Disorder

08.07.2008 27-08
NeuroSearch's TIPO-4 study with tesofensine confirms the efficacy in weight
management previously reported in TIPO-1 and provides the first long-term data
with an average weight loss of 13 to 14 kg

10.07.2008 28-08
NeuroSearch receives an IND approval from the FDA for ACR16 as part of an
ongoing pivotal clinical programme in Huntington's disease

11.08.2008 29-08
NeuroSearch reports final results from the TIPO-2 study with tesofensine in
obesity

27.08.2008 30-08
NeuroSearch announces revised financial calendar for 2008

27.08.2008 31-08
NeuroSearch A/S - Interim report for the first half-year of 2008

09.09.2008 32-08
NeuroSearch issues new shares in connection with exercise of warrants

30.09.2008 33-08
NeuroSearch A/S' share capital and voting rights

27.10.2008 34-08
NeuroSearch announces the dosing of the first patients in the US HART study, a
part of the ongoing ACR16 pivotal programme in Huntington's disease

17.11.2008 35-08
NeuroSearch A/S - Q3 report 2008

26.11.2008 36-08
NeuroSearch announces highly positive and supportive final results from a
cardiovascular safety evaluation study with the anti-obesity drug tesofensine

23.12.2008 37-08
NeuroSearch announces financial calendar for 2009

29.01.2009 01-09
NeuroSearch announce an expansion to their existing alliance with
GlaxoSmithKline

11.02.2009 02-09
NeuroSearch announces results from Phase II studies of ABT-894 in diabetic
neuropathic pain

17.02.2009 03-09
NeuroSearch announces drug discovery and development alliance with Eli Lilly
and Company

23.02.2009 04-09
NeuroSearch announces the results of Phase II Proof of Concept studies with
NS2359 in depression

02.03.2009 05-09
NeuroSearch regains global rights to ACR16

03.03.2009 06-09
NeuroSearch has issued 530,745 new shares in a directed offering subscribed by
Eli Lilly and Company in connection with the signing of a drug discovery and
development alliance

04.03.2009 07-09
NeuroSearch A/S Financial Statements 2008


Flemming Pedersen
CEO



Contact person:
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing
on ion channels and CNS disorders. A substantial share of NeuroSearch's
activities is partner financed through an alliance with Eli Lilly and Company
and collaborations with GlaxoSmithKline (GSK) and Abbott. The drug pipeline
comprises 8 clinical (Phase I-III) development programmes: ACR16 for
Huntington's disease (Phase III), tesofensine for obesity (Phase III ready),
ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 for Parkinson's
disease (Phase II ready), ABT-107 and ABT-560 for the treatment of various CNS
disorders - both (Phase I) in collaboration with Abbott, ACR343 for
schizophrenia (Phase II ready) and NSD-788 for anxiety/depression (Phase I). In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
holds equity interests in several biotech companies.

fonds.08-09 - selskabsmeddelelser i 2008-09 - uk.pdf